ArGEN-X focuses on the discovery and development of human antibodies using its proprietary SIMPLE Antibody (TM) platform. The platform generates a limitless source of extremely high quality human antibodies that modulate the function of disease targets, including complex receptors and highly conserved targets, that are not possible to generate with other antibody technologies. The Lead antibodies generated are further differentiated through enhancement of their cell killing properties (Potelligent® technology) and circulation time in the body (NHance™ technology). arGEN-X’s portfolio consists of novel programs addressing oncology, autoimmune and inflammation indications.
Total raised: $148.45M
Investors 2
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 03.06.2016 | - | $33M | - |
| 04.11.2013 | Series B | $44M | - |
| 01.12.2011 | Grant | $1.7M | - |
| 01.12.2011 | Series B | $37.05M | - |
| 03.12.2009 | Series A | $18.86M | - |
| 10.09.2009 | - | $13.84M | Forbion |
Mentions in press and media 20
| Date | Title | Description | Source |
| 18.05.2017 | Term Sheet — Thursday, May 18 | DOING THEIR OWN THING It’s fairly normal for successful venture capital pros to spend their careers... | fortune.co... |
| 09.05.2017 | Term Sheet — Tuesday, May 9 | PROFITABILITY OVER PASSION Land of Opportunity: Yesterday’s Term Sheet included a link to this stor... | fortune.co... |
| 24.04.2017 | Term Sheet — Monday, April 24 | OPEN MIC It’s feedback time. Paid Content Securing the enterprise without boundaries From ExtraHop... | fortune.co... |
| 24.04.2017 | NASDAQ bound: Argenx eyes a $75 million IPO | Argenx has raised significant cash to date through equity financing rounds and previous share offeri... | medcitynew... |
| 03.06.2016 | Fresh from its AbbVie cancer pact, argenx raises $33M with U... | After Belgium biotech argenx signed a preclinical immuno-oncology deal with U.S. giant AbbVie ($ABBV... | fiercebiot... |
| 07.11.2013 | arGEN-X Extends Series B Funds to $44M | BREDA, THE NETHERLANDS, arGEN-X, a biotech company developing therapeutic antibodies, has extended... | vcnewsdail... |
| 06.11.2013 | arGEN-X Raises Additional €5M in Series B Financing Round | arGEN-X, a Breda, The Netherlands- and Zwijnaarde, Belgium-based clinical state human therapeutic an... | finsmes.co... |
| 04.11.2013 | arGEN-X raises EUR 5 million from PMV in extension of EUR 32... | arGEN-X, a clinical stage human therapeutic antibody company, has raised EUR 5 million ($6.8 million... | forbion.co... |
| 16.05.2013 | With a band of biotech collaborators, RuiYi sets sail develo... | “There’s already an approved antibody that targets the receptor; ours targets the cytokine, so you c... | medcitynew... |
| 20.12.2011 | arGEN-X Receives €1.3M Grant | arGEN-X, a Rotterdam, The Nederlands-based biopharmaceutical company focused on the discovery and de... | finsmes.co... |
Show more